-
Achieve Life Sciences NasdaqCM:ACHV Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc., which is headquartered in Vancouver, Canada.
Location: 1040 West Georgia Street, Vancouver, BC, V6E 4H1, Canada | Website: https://www.achievelifesciences.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
110.9M
Cash
23.25M
Avg Qtr Burn
-8.893M
Short % of Float
8.97%
Insider Ownership
9.69%
Institutional Own.
41.59%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cytisinicline Details Smoking cessation | NDA Submission | |
Cytisinicline Details Smoking cessation | Phase 3 Initiation |